会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • High molecular weight polymer-based prodrugs
    • 高分子量聚合物基前药
    • US5965566A
    • 1999-10-12
    • US914927
    • 1997-08-20
    • Richard B. GreenwaldAnnapurna PendriHong Zhao
    • Richard B. GreenwaldAnnapurna PendriHong Zhao
    • A61K31/335A61K47/48C07D305/14C07D491/22C08G65/329A61K31/44
    • A61K47/48215A61K31/335C07D305/14C08G65/329
    • The present invention is directed compositions of the formula: ##STR1## wherein: D is a residue of biologically active moiety;X is an electron withdrawing group;Y and Y' are independently O or S;(n) is zero (0) or a positive integer, preferably from 1 to about 12;wherein: R.sub.1 and R.sub.2 are independently selected from the group consisting of H, C.sub.1-6 alkyls, aryls, substituted aryls, aralkyls, heteroalkyls, substituted heteroalkyls and substituted C.sub.1-6 alkyls;wherein: R.sub.3 is a substantially non-antigenic polymer, C.sub.1-12 straight or branched alkyl or substituted allyl, C.sub.5-8 cycloalkyl or substituted cycloalkyl, carboxyalkyl, carboalkoxy alkyl, dialkylaminoalkyl, phenylalkyl, phenylaryl or ##STR2## wherein: R.sub.4 and R.sub.5 are independently selected from the group consisting of H, C.sub.1-6 alkyls, aryls, substituted aryls, aralkyls, heteroalkyls, substituted heteroalkyls, and substituted C.sub.1-6 alkyls or jointly form a cyclic C.sub.5 -C.sub.7 ring. In preferred embodiments, the prodrugs contain a polyethylene glycol having a molecular weight of at least about 20,000.
    • 本发明涉及下式的组合物:其中:D是生物活性部分的残基; X是吸电子基团; Y和Y'独立地为O或S; (n)为零(0)或正整数,优选1至约12; 其中:R 1和R 2独立地选自H,C 1-6烷基,芳基,取代的芳基,芳烷基,杂烷基,取代的杂烷基和取代的C 1-6烷基; 其中:R3是基本上非抗原性的聚合物,C1-12直链或支链烷基或取代的烯丙基,C5-8环烷基或取代的环烷基,羧基烷基,烷氧基烷基,二烷基氨基烷基,苯基烷基,苯基芳基或其中:R4和R5独立地选自 由H,C 1-6烷基,芳基,取代的芳基,芳烷基,杂烷基,取代的杂烷基和取代的C 1-6烷基组成的基团或共同形成环状C 5 -C 7环。 在优选的实施方案中,前药包含分子量为至少约20,000的聚乙二醇。
    • 8. 发明授权
    • Terminally-branched polymeric linkers and polymeric conjugates containing the same
    • 末端支化的聚合物接头和含有它们的聚合物共轭物
    • US06638499B2
    • 2003-10-28
    • US10067930
    • 2002-02-06
    • Anthony J. MartinezAnnapurna PendriRichard B. GreenwaldYun H. Choe
    • Anthony J. MartinezAnnapurna PendriRichard B. GreenwaldYun H. Choe
    • A61K31785
    • C07D491/22A61K47/60C07H15/252C08F283/00
    • The present invention is directed to polymeric-prodrug transport forms of the formula: wherein: E1-4 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy, C1-6 heteroalkoxy, and at least one of E1-4 includes a B moiety, wherein B is a leaving group, OH, a residue of a hydroxyl-or amino-containing moiety or wherein J1 is the same as J, or another member of the group defining J and E5 is the same as E1-4, or another member of the group defining E1-4, Y1-2 are independently O, S or NR9; M is a heteroatom selected from either X or Q; wherein X is an electron withdrawing group and Q is a moiety containing a free electron pair positioned three to six atoms from C(═Y2); R2-5 and R7-9 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroakoxy; (m1) and (m2) are independently zero or one; (n1), (n2), (p1), (p2) and (q) are independently zero or a positive integer, Z is an electron withdrawing group; and R1 is a polymeric residue. which is optionally capped with a moiety of the formula:
    • 本发明涉及下式的聚合物 - 前药转运形式:其中:E1-4独立地选自氢,C 1-6烷基,C 3-12支链烷基,C 3-8环烷基,C 1-6取代的 烷基,C 3-8取代的环烷基,芳基,取代的芳基,芳烷基,C 1-6杂烷基,取代的C 1-6杂烷基,C 1-6烷氧基,苯氧基,C 1-6杂烷氧基,E1-4中的至少一个包括B部分 其中B是离去基团,OH,含羟基或氨基的部分的残基或其中J 1与J相同,或者定义J和E5的基团的另一个成员与E1-4相同或另一个成员 定义E1-4的基团,Y1-2独立地为O,S或NR9; M为选自X或Q的杂原子; 其中X是吸电子基团,Q是含有从C(= Y2)定位为三至六个原子的自由电子对的部分; R2-5和R7-9独立地选自氢,C1-6烷基 ,C3-12支链烷基,C3-8环烷基,C1-6取代的烷基,C3-8取代的环烷基,芳基,取代的芳基,芳烷基,C1-6杂烷基,取代的C1-6杂烷基,C1-6烷氧基,苯氧基和C1 -6杂芳氧基;(m1)和(m2)分别为零或一;(n1),(n2),(p1),(p2)和(q)分别为零或正整数,Z为吸电子基团 ; 并且R 1是聚合物残基,其任选地被下式的部分封端:
    • 9. 发明授权
    • Terminally-branched polymeric linkers and polymeric conjugates containing the same
    • 末端支化的聚合物接头和含有它们的聚合物共轭物
    • US06395266B1
    • 2002-05-28
    • US09293624
    • 1999-04-16
    • Anthony J. MartinezAnnapurna PendriRichard B. GreenwaldYun H. Choe
    • Anthony J. MartinezAnnapurna PendriRichard B. GreenwaldYun H. Choe
    • A61K31785
    • C07D491/22A61K47/60C07H15/252C08F283/00
    • The present invention is directed to polymeric-prodrug transport forms of the formula: wherein: E1-4 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy, C1-6 heteroalkoxy, and at least one of E1-4 includes a B moiety, wherein B is a leaving group, OH, a residue of a hydroxyl-or amino-containing moiety or wherein J1 is the same as J, or another member of the group defining J and E5 is the same as E1-4, or another member of the group defining E1-4; Y1-2 are independently O, S or NR9; M is a heteroatom selected from either X or Q; wherein X is an electron withdrawing group and Q is a moiety containing a free electron pair positioned three to six atoms from C(=Y2); R2-5 and R7-9 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-16 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy; (m1) and (m2) are independently zero or one; (n1), (n2), (p1), (p2) and (q) are independently zero or a positive integer, Z is an electron withdrawing group; and R1 is a polymeric residue. which is optionally capped with a moiety of the formula:
    • 本发明涉及下式的聚合物 - 前药转运形式:其中:E1-4独立地选自氢,C 1-6烷基,C 3-12支链烷基,C 3-8环烷基,C 1-6取代的 烷基,C 3-8取代的环烷基,芳基,取代的芳基,芳烷基,C 1-6杂烷基,取代的C 1-6杂烷基,C 1-6烷氧基,苯氧基,C 1-6杂烷氧基,E1-4中的至少一个包括B部分 其中B是离去基团,OH,含羟基或氨基的部分的残基或其中J 1与J相同,或者定义J和E5的基团的另一个成员与E1-4相同或另一个成员 定义E1-4的基团; Y1-2独立地为O,S或NR9; M为选自X或Q的杂原子; 其中X是吸电子基团,Q是含有从C(= Y2)定位为三至六个原子的自由电子对的部分; R2-5和R7-9独立地选自氢,C1-6烷基 ,C3-12支链烷基,C3-8环烷基,C1-6取代烷基,C3-8取代环烷基,芳基,取代芳基,芳烷基,C1-16杂烷基,取代C1-6杂烷基,C1-6烷氧基,苯氧基和C1 -6杂烷氧基;(m1)和(m2)独立为零或一;(n1),(n2),(p1),(p2)和(q)独立为零或正整数,Z为吸电子基团 ; 并且R 1是聚合物残基,其任选地被下式的部分封端: